Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-337-4680
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees111
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions
What is Solid Biosciences' stock symbol?
Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."
How were Solid Biosciences' earnings last quarter?
Solid Biosciences Inc (NASDAQ:SLDB) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.
When is Solid Biosciences' next earnings date?
What price target have analysts set for SLDB?
8 Wall Street analysts have issued 1-year target prices for Solid Biosciences' stock. Their forecasts range from $4.00 to $22.00. On average, they expect Solid Biosciences' share price to reach $10.50 in the next twelve months. This suggests that the stock has a possible downside of 18.6%. View Analyst Price Targets for Solid Biosciences.
What is the consensus analysts' recommendation for Solid Biosciences?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.
Has Solid Biosciences been receiving favorable news coverage?
Headlines about SLDB stock have trended negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Solid Biosciences earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Solid Biosciences.
Are investors shorting Solid Biosciences?
Solid Biosciences saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 3,320,000 shares, a decrease of 11.0% from the August 15th total of 3,730,000 shares. Based on an average trading volume of 560,200 shares, the days-to-cover ratio is currently 5.9 days. Currently, 11.0% of the company's stock are sold short. View Solid Biosciences' Current Options Chain.
Who are some of Solid Biosciences' key competitors?
Some companies that are related to Solid Biosciences include Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), SpringWorks Therapeutics (SWTX), BAVARIAN NORDIC/S (BVNRY) and Twist Bioscience (TWST).
What other stocks do shareholders of Solid Biosciences own?
Who are Solid Biosciences' key executives?
Solid Biosciences' management team includes the folowing people:
- Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
- Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
- Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
- Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
- Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)
When did Solid Biosciences IPO?
(SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.
How do I buy shares of Solid Biosciences?
Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Solid Biosciences' stock price today?
One share of SLDB stock can currently be purchased for approximately $12.90.
How big of a company is Solid Biosciences?
Solid Biosciences has a market capitalization of $593.40 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.
What is Solid Biosciences' official website?
How can I contact Solid Biosciences?
Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.
MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
